Tara K Lafferty
Overview
Explore the profile of Tara K Lafferty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
10
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeng X, Sehrawat A, Lafferty T, Chen Y, Rawat M, Kamboh M, et al.
Alzheimers Dement
. 2025 Feb;
21(2):e14535.
PMID: 39989429
Introduction: Proteomic evaluation of plasma samples could accelerate the identification of novel Alzheimer's disease (AD) biomarkers. We evaluated the novel NUcleic acid Linked Immuno-Sandwich Assay (NULISA) proteomic method in an...
2.
Olvera-Rojas M, Sewell K, Karikari T, Huang H, Oberlin L, Zeng X, et al.
Alzheimers Dement
. 2024 Dec;
21(2):e14430.
PMID: 39641408
Introduction: Blood-based biomarkers (BBMs) can enable early detection of brain amyloid beta (Aβ) pathology in cognitively unimpaired individuals. However, the extent to which common medical conditions affect biomarker performance remains...
3.
Gildengers A, Weinstein A, Gujral S, Zeng X, Diaz J, Lafferty T, et al.
Am J Geriatr Psychiatry
. 2024 Oct;
33(4):428-437.
PMID: 39448295
Objectives: We examine the clinical utility of plasma-based detection for Alzheimer's disease (AD) pathophysiology in older adults with mild cognitive impairment (MCI) and whether cognitive screening can inform when to...
4.
Zeng X, Lafferty T, Sehrawat A, Chen Y, Ferreira P, Bellaver B, et al.
Mol Neurodegener
. 2024 Oct;
19(1):68.
PMID: 39385222
Background: Blood-based biomarkers are gaining grounds for the detection of Alzheimer's disease (AD) and related disorders (ADRDs). However, two key obstacles remain: the lack of methods for multi-analyte assessments and...
5.
Zeng X, Lafferty T, Sehrawat A, Chen Y, Ferreira P, Bellaver B, et al.
medRxiv
. 2024 Jul;
PMID: 38947065
Background: Blood-based biomarkers are gaining grounds for Alzheimer's disease (AD) detection. However, two key obstacles need to be addressed: the lack of methods for multi-analyte assessments and the need for...
6.
Chen Y, Zeng X, Diaz J, Sehrawat A, Lafferty T, Boslett J, et al.
J Neurochem
. 2024 May;
168(9):2736-2750.
PMID: 38814273
The reliability of plasma biomarkers of Alzheimer's disease (AD) can be compromised by protease-induced degradation. This can limit the feasibility of conducting plasma biomarker studies in environments that lack the...
7.
Zeng X, Chen Y, Sehrawat A, Lee J, Lafferty T, Kofler J, et al.
Mol Neurodegener
. 2024 May;
19(1):40.
PMID: 38750570
Alzheimer's disease (AD), the most common form of dementia, remains challenging to understand and treat despite decades of research and clinical investigation. This might be partly due to a lack...
8.
Chen Y, Zeng X, Lee J, Sehrawat A, Lafferty T, Boslett J, et al.
medRxiv
. 2024 Mar;
PMID: 38496591
Introduction: The reliability of plasma Alzheimer's disease (AD) biomarkers can be compromised by protease-induced degradation. This limits the feasibility of conducting plasma biomarker studies in environments that lack the capacity...